<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
<journal-title-group>
<journal-title>Translational Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">2158-3188</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28763059</article-id>
<article-id pub-id-type="pmc">5611740</article-id>
<article-id pub-id-type="pii">tp2017173</article-id>
<article-id pub-id-type="doi">10.1038/tp.2017.173</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rare genetic variants in <italic>CX3CR1</italic> and their contribution to the increased
risk of schizophrenia and autism spectrum disorders</article-title>
<alt-title alt-title-type="running">Rare <italic>CX3CR1</italic> variants associated with SCZ and ASD</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ishizuka</surname>
<given-names>K</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fujita</surname>
<given-names>Y</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kawabata</surname>
<given-names>T</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kimura</surname>
<given-names>H</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iwayama</surname>
<given-names>Y</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Inada</surname>
<given-names>T</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Okahisa</surname>
<given-names>Y</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Egawa</surname>
<given-names>J</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Usami</surname>
<given-names>M</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kushima</surname>
<given-names>I</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uno</surname>
<given-names>Y</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Okada</surname>
<given-names>T</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ikeda</surname>
<given-names>M</given-names>
</name>
<xref ref-type="aff" rid="aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aleksic</surname>
<given-names>B</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8982-4580</contrib-id>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mori</surname>
<given-names>D</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Someya</surname>
<given-names>To</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yoshikawa</surname>
<given-names>T</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iwata</surname>
<given-names>N</given-names>
</name>
<xref ref-type="aff" rid="aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nakamura</surname>
<given-names>H</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yamashita</surname>
<given-names>T</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ozaki</surname>
<given-names>N</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7360-4898</contrib-id>
</contrib>
<aff id="aff1"><label>1</label><institution>Department of Psychiatry, Nagoya
University Graduate School of Medicine</institution>, Nagoya,
<country>Japan</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Molecular Neuroscience,
Osaka University Graduate School of Medicine</institution>, Osaka,
<country>Japan</country></aff>
<aff id="aff3"><label>3</label><institution>Institute for Protein Research, Osaka
University</institution>, Osaka, <country>Japan</country></aff>
<aff id="aff4"><label>4</label><institution>Laboratory for Molecular Psychiatry,
RIKEN Brain Science Institute</institution>, Wako, <country>Japan</country></aff>
<aff id="aff5"><label>5</label><institution>Department of Neuropsychiatry, Okayama
University Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences</institution>, Okayama, <country>Japan</country></aff>
<aff id="aff6"><label>6</label><institution>Department of Psychiatry, Niigata
University Graduate School of Medical and Dental Sciences</institution>,
Niigata, <country>Japan</country></aff>
<aff id="aff7"><label>7</label><institution>Department of Child and Adolescent
Psychiatry, Kohnodai Hospital, National Center for Global Health and
Medicine</institution>, Ichikawa, <country>Japan</country></aff>
<aff id="aff8"><label>8</label><institution>Laboratory for Psychiatric and Molecular
Neuroscience, McLean Hospital</institution>, Belmont, MA,
<country>USA</country></aff>
<aff id="aff9"><label>9</label><institution>Department of Psychiatry, Fujita Health
University School of Medicine</institution>, Toyoake, <country>Japan</country></aff>
<aff id="aff10"><label>10</label><institution>Brain and Mind Research Center, Nagoya
University</institution>, Nagoya, <country>Japan</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Department of Psychiatry, Nagoya University Graduate School
of Medicine</institution>, 65 Tsurumai-cho, Showa-ku,
Nagoya, Aichi
4668550, <country>Japan</country>. E-mail: <email>branko@med.nagoya-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>08</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>01</day>
<month>08</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>8</month>
<year>2017</year>
</pub-date>
<volume>7</volume>
<issue>8</issue>
<fpage>e1184</fpage>
<lpage></lpage>
<history>
<date date-type="received">
<day>09</day>
<month>03</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>20</day>
<month>05</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>06</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 The Author(s)</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>The Author(s)</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--author-paid-->
<license-p>This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other
third party material in this article are included in the article’s Creative
Commons license, unless indicated otherwise in the credit line; if the material is
not included under the Creative Commons license, users will need to obtain permission
from the license holder to reproduce the material. To view a copy of this license,
visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
</license>
</permissions>
<abstract>
<p>CX3CR1, a G protein-coupled receptor solely expressed by microglia in the brain, has
been repeatedly reported to be associated with neurodevelopmental disorders including
schizophrenia (SCZ) and autism spectrum disorders (ASD) in transcriptomic and animal
studies but not in genetic studies. To address the impacts of variants in
<italic>CX3CR1</italic> on neurodevelopmental disorders, we conducted coding exon-targeted
resequencing of <italic>CX3CR1</italic> in 370 Japanese SCZ and 192 ASD patients using
next-generation sequencing technology, followed by a genetic association study in a
sample comprising 7054 unrelated individuals (2653 SCZ, 574 ASD and 3827 controls).
We then performed <italic>in silico</italic> three-dimensional (3D) structural modeling and
<italic>in vivo</italic> disruption of Akt phosphorylation to determine the impact of the
detected variant on CX3CR1-dependent signal transduction. We detected a statistically
significant association between the variant Ala55Thr in <italic>CX3CR1</italic> with SCZ and
ASD phenotypes (odds ratio=8.3, <italic>P</italic>=0.020). A 3D structural
model indicated that Ala55Thr could destabilize the conformation of the CX3CR1 helix
8 and affect its interaction with a heterotrimeric G protein. <italic>In vitro</italic>
functional analysis showed that the CX3CR1-Ala55Thr mutation inhibited cell signaling
induced by fractalkine, the ligand for CX3CR1. The combined data suggested that the
variant Ala55Thr in CX3CR1 might result in the disruption of CX3CR1 signaling. Our
results strengthen the association between microglia-specific genes and
neurodevelopmental disorders.</p>
</abstract>
</article-meta>
</front>
<body>
<sec>
<title>Introduction</title>
<p>Both schizophrenia (SCZ) and autism spectrum disorders (ASD) are highly polygenic
neurodevelopmental disorders. SCZ and ASD share etiological, clinical and biological
features.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref></sup> The prevalence and recurrence risks to relatives are nearly
identical, and heritability is estimated to be a minimum of 80% for each
disorder.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> Genetic contributions have
played a major role in the etiology of both disorder; however, these genetic
components are still unclear. As thousands of trait- and disease-associated common
genetic variants of small effect may explain less than half of the total variation
responsible for increased risk of developing either disorder,<sup><xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref></sup> a significant excess of rare, disruptive variants (with a
frequency &lt;1%) have provided additional genetic risk of these complex
disorders or trait variability.<sup><xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">8</xref>, <xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib11">11</xref></sup> In particular, many
genes with rare variants that are common to both SCZ and ASD are related to synapse
morphogenesis.<sup><xref ref-type="bibr" rid="bib12">12</xref>, <xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref>, <xref ref-type="bibr" rid="bib15">15</xref></sup></p>
<p>Recent evidence implicates synaptic formation as an important factor in the
pathogenesis of SCZ and ASD.<sup><xref ref-type="bibr" rid="bib12">12</xref>, <xref ref-type="bibr" rid="bib16">16</xref></sup> It is becoming clear that microglia, which are
the resident macrophages and phagocytes of the central nerve system, contribute to
major aspects of the structural shaping and functional modulation of the connectivity
of the developing and healthy brain.<sup><xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib21">21</xref></sup> Aberrant
functions of microglia have potential implication for SCZ and ASD.<sup><xref ref-type="bibr" rid="bib22">22</xref>, <xref ref-type="bibr" rid="bib23">23</xref>, <xref ref-type="bibr" rid="bib24">24</xref>, <xref ref-type="bibr" rid="bib25">25</xref></sup> Altered gene
expression of microglia has been found in the brains of SCZ<sup><xref ref-type="bibr" rid="bib26">26</xref>, <xref ref-type="bibr" rid="bib27">27</xref></sup> and ASD
patients.<sup><xref ref-type="bibr" rid="bib28">28</xref></sup> Transcriptomic studies of
post-mortem brains have demonstrated dysregulation of microglial gene expression in
SCZ<sup><xref ref-type="bibr" rid="bib29">29</xref></sup> and ASD.<sup><xref ref-type="bibr" rid="bib30">30</xref></sup> Microglial synapse morphogenesis is dependent on
the receptor CX3C chemokine receptor 1 (CX3CR1, also known as fractalkine receptor,
OMIM: 601470), which is solely expressed by microglia in the brain<sup><xref ref-type="bibr" rid="bib19">19</xref></sup> and has been proposed as a key mediator of
neuron–microglia interactions.<sup><xref ref-type="bibr" rid="bib31">31</xref></sup> Mice
lacking <italic>Cx3cr1</italic> exhibit deficits in synaptic pruning<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib33">33</xref>, <xref ref-type="bibr" rid="bib34">34</xref></sup> as well as in social interaction and increased
repetitive-behavior phenotypes, which is considered to be the core symptoms of
ASD.<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib34">34</xref></sup> These findings strongly support the notion that
<italic>CX3CR1</italic> is a plausible candidate risk gene for SCZ and/or ASD.</p>
<p>To date, two <italic>CX3CR1</italic> polymorphism, Var249Ile (rs3732379) and Thr280Met
(rs3732378), have been reported to affect the activity of the CX3CR1 protein. These
polymorphisms are associated with several neuroinflammatory disorders such as HIV-1
infection,<sup><xref ref-type="bibr" rid="bib35">35</xref></sup> multiple
sclerosis,<sup><xref ref-type="bibr" rid="bib36">36</xref></sup> amytrophic lateral
sclerosis,<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> age-related macular
degeneration<sup><xref ref-type="bibr" rid="bib38">38</xref></sup> and coronary
atherosclerosis.<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> However, the
effects of these common variants on disease pathogenesis are quite
small.<sup><xref ref-type="bibr" rid="bib35">35</xref>, <xref ref-type="bibr" rid="bib36">36</xref>, <xref ref-type="bibr" rid="bib37">37</xref>, <xref ref-type="bibr" rid="bib38">38</xref></sup> There has been no published report of causal genetic
variants of <italic>CX3CR1</italic> in cases with neurodevelopmental disorders including SCZ
and ASD. We therefore hypothesized that a rare variant of the microglia-specific
<italic>CX3CR1</italic> gene would contribute to some pathophysiological mechanisms of
these neurodevelopmental disorders.<sup><xref ref-type="bibr" rid="bib40">40</xref></sup> To
increase statistical power and detect shared risk, we combined SCZ and ASD samples in
a study cohort.<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib15">15</xref></sup></p>
<p>We then performed <italic>in silico</italic> three-dimensional (3D) structural modeling and
<italic>in vivo</italic> disruption of Akt phosphorylation to determine the impact of the
detected variant on CX3CR1-dependent signal transduction based on the following: (i)
CX3CR1 is a seven transmembrane domain G protein-coupled receptor (GPCR), the
signaling systems of which are involved in many disease and major therapeutic
targets.<sup><xref ref-type="bibr" rid="bib41">41</xref></sup> (ii) The chemokine
fractalkine, the sole ligand for CX3CR1, is known to activate the Akt signaling
pathways through CX3CR1.<sup><xref ref-type="bibr" rid="bib42">42</xref>, <xref ref-type="bibr" rid="bib43">43</xref>, <xref ref-type="bibr" rid="bib44">44</xref>, <xref ref-type="bibr" rid="bib45">45</xref>, <xref ref-type="bibr" rid="bib46">46</xref></sup></p>
<p>In this study, we present the genetic association of a variant in <italic>CX3CR1</italic>
with SCZ and ASD, followed by <italic>in silico</italic> 3D structural modeling of the
predicted conformational change of the variant receptor and its <italic>in vivo</italic>
disruption of the Akt signaling. Our findings provide the genetic evidence of the
association of a microglia-specific gene with neurodevelopmental disorders.</p>
</sec>
<sec>
<title>Materials and methods</title>
<sec>
<title>Study samples</title>
<p>Two independent Japanese sample groups were used in this study. The
targeted-resequencing discovery cohort comprised 370 SCZ (mean age±s.d.,
49.7±14.8 years; 53% male) and 192 ASD (mean
age±s.d.=16.3±8.4 years; 77.6% male). For the genetic
association analysis, the case–control sample set comprised 2283 SCZ
(48.1±23.8 years; 41.7% male), 382 ASD (19.6±10.7 years;
77.8% male) and 3827 control subjects (43.3±14.5 years; 41.6%
male). All subjects were unrelated, living on the mainland of Japan, and
self-identified as Japanese. All patients fulfilled the criteria listed in the
<italic>Diagnostic and Statistical Manual of Mental Disorders,</italic> Fifth Edition
(DSM-5) for SCZ or ASD. Healthy control subjects were selected from the general
population and had no history of mental disorders based on questionnaire responses
from the subjects themselves during the sample inclusion step. The study was
explained to each participant and/or their parents both verbally and in
writing. Written informed consent was obtained from the participants and from the
parents for patients under 20 years old. All procedures performed in this study
involving human participants were approved by the Ethics Committee of the Nagoya
University Graduate School of Medicine. They were conducted in accordance with the
Helsinki Declaration of 1975 and its later amendments or comparable ethical
standards.</p>
</sec>
<sec>
<title>Sample preparation</title>
<p>Genomic DNA was extracted from peripheral blood or saliva from each SCZ, ASD and
control participant using the QIAamp DNA Blood Kit or Tissue Kit (Qiagen, Hilden,
Germany). The quantity of extracted DNA was estimated using the Qubit dsDNA BR
Assay Kit (Life Technologies, Carlsbad, CA, USA) on a Qubit 2.0 Fluorometer (Life
Technologies) following the manufacturer’s recommended protocol.</p>
</sec>
<sec>
<title>Library preparation and resequencing</title>
<p>We used the next-generation sequencing technology of the Ion Torrent PGMto
resequence the <italic>CX3CR1</italic> coding regions (Ensembl Transcript ID:
ENST00000399220, NCBI reference sequence NM_001337.3, NP_001328.1; 355 amino
acids) via the protocols described in the Ion AmpliSeq Library Preparation User
Guide (Thermo Fisher Scientific, Waltham, MA, USA, Rev.5; MAN0006735), the Ion PGM
Template OT2 200 Kit (Thermo Fisher Scientific, Rev. 5; MAN0007220) and the Ion
PGM Sequencing 200 Kit (Thermo Fisher Scientific, Rev. 3; MAN0007273). Custom
amplification primers were designed to cover coding exons and flanking intron
regions of the selected genes with Ion AmpliSeq Designer (Thermo Fisher
Scientific). Sample amplification and equalization were achieved using Ion
AmpliSeq Library Kits 2.0 and the Ion Library Equalizer Kit, respectively (Thermo
Fisher Scientific). Amplified sequences were ligated with Ion Xpress Barcode
Adapters (Thermo Fisher Scientific). Emulsion PCR and subsequent enrichment were
performed using the Ion OneTouch Template Kit v2.0 on Ion OneTouch 2 and Ion
OneTouch ES, respectively (Thermo Fisher Scientific).</p>
</sec>
<sec>
<title>Data analysis</title>
<p>Sequence reads were run through a data analysis pipeline of the Ion Torrent
platform-specific pipeline software, Torrent Suite version 4.4 (Life Technologies)
to generate sequence reads filtered according to the pipeline software
quality-controls and to remove poor signal reads. Reads assembly and variant
identification were performed using the Ingenuity Variant Analysis software
(<ext-link ext-link-type="uri" xlink:href="http://www.ingenuity.com/variants" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.ingenuity.com/variants</ext-link>) from Ingenuity Systems using
Fastq files containing sequence reads and the Ion Ampliseq Designer BED file
software to map the amplicons with default parameters (call quality &gt;20 and
read depth &gt;10).</p>
<p>Candidate variants were defined as exonic or splice-site variants with allele
frequencies of ⩽1% in the following three public exome databases: dbSNP
Build 149 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.ncbi.nlm.nih.gov/projects/SNP/</ext-link>); the 1000 Genomes Project
(<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.1000genomes.org</ext-link>); and the Exome Aggregation Consortium
(ExAC) (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://exac.broadinstitute.org</ext-link>). We then examined two databases as a
reference for Japanese controls: the Human Genetic Variation Database (HGVD)
(<ext-link ext-link-type="uri" xlink:href="http://www.genome.med.kyoto-u.ac.jp/SnpDB/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.genome.med.kyoto-u.ac.jp/SnpDB/</ext-link>) and the integrative
Japanese Genome Variation Database (iJGVD) (<ext-link ext-link-type="uri" xlink:href="https://ijgvd.megabank.tohoku.ac.jp" xmlns:xlink="http://www.w3.org/1999/xlink">https://ijgvd.megabank.tohoku.ac.jp</ext-link>).<sup><xref ref-type="bibr" rid="bib47">47</xref></sup> Prediction of significance was performed using
PolyPhen-2 (last accessed Feb 2017; <ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/" xmlns:xlink="http://www.w3.org/1999/xlink">http://genetics.bwh.harvard.edu/pph2/</ext-link>)<sup><xref ref-type="bibr" rid="bib48">48</xref></sup> and MutationTaster (last accessed Feb 2017; <ext-link ext-link-type="uri" xlink:href="http://www.mutationtaster.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.mutationtaster.org</ext-link>).<sup><xref ref-type="bibr" rid="bib49">49</xref></sup> Additional clinical variant annotations were obtained
from NCBI ClinVar (last accessed Feb 2017; <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/clinvar/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.ncbi.nlm.nih.gov/clinvar/</ext-link>)<sup><xref ref-type="bibr" rid="bib50">50</xref></sup> and DECIPHER v9.12 (last accessed Feb 2017; <ext-link ext-link-type="uri" xlink:href="https://decipher.sanger.ac.uk" xmlns:xlink="http://www.w3.org/1999/xlink">https://decipher.sanger.ac.uk</ext-link>).<sup><xref ref-type="bibr" rid="bib51">51</xref></sup> Localization of a protein domain was based on the human
protein reference database (<ext-link ext-link-type="uri" xlink:href="http://www.hprd.org/index.html" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.hprd.org/index.html</ext-link>) (HPRD). When available,
parents were sequenced to determine inheritance patterns. All candidate variants
were confirmed by Sanger sequencing with the ABI 3130xl Genetic Analyzer (Life
Technologies) with standard methods. Sequence analysis software version 6.0
(Applied Biosystems, Foster City, CA, USA) was used to analyze all sequence data.
Primer sequences for validating each variant are available in <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S3</xref>.</p>
</sec>
<sec>
<title>Genetic association analysis</title>
<p>The effective sample size and statistical power was computed using the web browser
program, Genetic Power Calculator, developed by Purcell <italic>et al.</italic> (<ext-link ext-link-type="uri" xlink:href="http://pngu.mgh.harvard.edu/~purcell/gpc/" xmlns:xlink="http://www.w3.org/1999/xlink">http://pngu.mgh.harvard.edu/~purcell/gpc/</ext-link>).<sup><xref ref-type="bibr" rid="bib52">52</xref></sup> An ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems) and TaqMan assays with custom probes were used to genotype a putative
deleterious variant. Custom probe sequences are indicated in <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S4</xref>. Each 384-microtiter plate contained two
non-template controls and two samples with the variant. The reactions and data
analysis were performed using Genotyping Master Mix and Sequence Detection
Systems, respectively, according to standard protocols (Applied Biosystems).
Differences in genotype distribution between cases and controls were tested with
one-sided, Fisher’s exact tests.</p>
</sec>
<sec>
<title>Phenotypic analysis</title>
<p>The clinical features of patients with the variant that was possibly associated
with SCZ and ASD phenotypes based on genetic association analysis were examined
retrospectively from medical records. All comorbidities were diagnosed by
experienced psychiatrists according to DSM-5 criteria.</p>
</sec>
<sec>
<title>Modeling of the 3D structure of CX3CR1-Ala55Thr</title>
<p>A 3D structure of CX3CR1 could be modeled using a homology modeling technique,
because many 3D structures of members of the GPCR family have been solved
recently. The 3D structure of CCR2 isoform B<sup><xref ref-type="bibr" rid="bib53">53</xref></sup> was chosen as the template for this modeling (PDBcode:
5t1a), as this structure was the closest homolog to CX3CR1 that was found by the
BLAST program in the 3D structural database.<sup><xref ref-type="bibr" rid="bib54">54</xref></sup> The sequence identity between CX3CR1 and CCR2 isoform B is
about 46%. The template structure and the BLAST alignment were downloaded
from the HOMCOS server,<sup><xref ref-type="bibr" rid="bib55">55</xref></sup> and manually
modified to remove the region of T4 lysozome in the structure. The program
MODELLER 9.16 was used for the modeling.<sup><xref ref-type="bibr" rid="bib56">56</xref></sup> Bound structures of membrane, fractalkine and
heterotrimeric G protein were modeled by 3D superimpositions. 3D structures of
GPCR in complexes were superimposed on the CX3CR1 model using the program
MATRAS,<sup><xref ref-type="bibr" rid="bib57">57</xref></sup> and bound molecules in
the complexes were also transformed with their GPCRs. The membrane model used was
taken from a molecular dynamics study of GPCRs.<sup><xref ref-type="bibr" rid="bib58">58</xref></sup> The fractalkine structure was obtained from a complex of
fractalkine with a viral GPCR (PDBcode: 4xt1).<sup><xref ref-type="bibr" rid="bib59">59</xref></sup> The structure of a heterotrimeric G protein (Gα,
Gβ, Gγ) was taken from a G protein complex with the β2 adrenergic
receptor (PDBcode: 3sn6).<sup><xref ref-type="bibr" rid="bib60">60</xref></sup></p>
</sec>
<sec>
<title>Functional analysis of CX3CR1-Ala55Thr; effect on Akt
phosphorylation-mediated signaling</title>
<p>The cDNA of human CX3CR1 was amplified from the IMAGE clone 5216452, and was
inserted into the pmCherry vector (Clontech, Palo Alto, CA, USA) using Bgl2 and
EcoR1. For the construction of pmCherry-Cx3cr1 Ala55Thr, site-specific mutagenesis
was carried out using the KOD-Plus-Mutagenesis Kit (TOYOBO, Shiga, Japan) with
pmCherry-Cx3cr1 wild-type (WT) as a template. The following primers were used for
mutagenesis: (1) forward
5′-GTGTTTACCCTCACCAACAGCAAGA-3′ and (2) reverse
5′-TACCAACAAATTTCCCACCAGGCCA-3′.</p>
<p>Cells of the human embryonic kidney cell line, HEK293, were cultured in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
and 50 U penicillin–streptomycin at 37 °C with 5%
CO<sub>2</sub> inside a humidified incubator. Cells were transiently
transfected with the pmCherry-Cx3cr1 WT or Ala55Thr plasmid by using Lipofectamine
2000 (Invitrogen), and cultured for 36 h. Then, the cells were fixed with
4% paraformaldehyde for 30 min and washed with PBS. Subsequently,
the cells were mounted with a fluorescence mounting medium (DakoCytomation,
Glostrup, Denmark). Images were acquired on a microscope (BX51; Olympus, Tokyo,
Japan) equipped with a sCMOS camera (Zyla; Andor Technology, Belfast, UK).</p>
<p>For western blotting, the cells were transfected with the pmCherry-Cx3cr1 WT or
Ala55Thr plasmid, cultured for 36 h, and then stimulated with fractalkine
(R&amp;D systems, Minneapolis, MN, USA) for 15 min. The cell lysates were
boiled in sample buffer for 5 min. The proteins were separated by SDS-PAGE
and transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA,
USA). The membrane was blocked with 5% non-fat dry milk in PBS containing
0.05% Tween-20 (PBS-T) and incubated for 1 h at room temperature
with the primary antibody diluted in PBS-T containing 1% non-fat dry milk.
After washing in PBS-T, the membrane was incubated with an HRP-conjugated
anti-rabbit IgG antibody (Cell Signaling Technology, Danvers, MA, USA). The ECL
chemiluminescence system (GE Healthcare, Waukesha, WI, USA) was used for signal
detection. Signals were detected using the Amersham Imager 600 (GE Healthcare),
and were quantified using Image J software (NIH, Bethesda, MD, USA, in public
domain software).</p>
</sec>
</sec>
<sec>
<title>Results</title>
<sec>
<title>Screening of variation in CX3CR1 coding exons</title>
<p>Nucleotide sequence data have been submitted to the DNA Data Bank of Japan (DDBJ)
databases (<ext-link ext-link-type="uri" xlink:href="http://www.ddbj.nig.ac.jp" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.ddbj.nig.ac.jp</ext-link>) under the accession number DRA004490. We
identified three rare missense heterozygous variants within <italic>CX3CR1</italic> coding
regions in genomic DNA isolated from Japanese SCZ or ASD patient samples
(<italic>n</italic>=562). All of the single nucleotide variants (SNVs) were
validated by Sanger sequencing (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="table" rid="tbl1">Table 1</xref>). Nonsense variants, frameshift variants and
splicing-site variants were not found. Genomic DNA of the parents was available
for three of seven subjects carrying these three rare missense variants. In these
three pedigrees, the variants were found to be transmitted from a parent
(<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>). None of SNVs
detected in our study were registered in ClinVar nor in the DECIPHER database.</p>
</sec>
<sec>
<title>Genetic association of CX3CR1-Ala55Thr with SCZ and ASD</title>
<p>Of these three SNVs, we focused on the Ala55Thr variant because it was detected in
two unrelated cases in a 562-patient cohort and was present in only one of the
60,360 Exome Aggregation Consortium (ExAC) cohort (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://exac.broadinstitute.org</ext-link>) (<xref ref-type="table" rid="tbl1">Table
1</xref>), whereas the Gly112 Ala variant was registered in Japanese
databases: the HGVD (<ext-link ext-link-type="uri" xlink:href="http://www.genome.med.kyoto-u.ac.jp/SnpDB/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.genome.med.kyoto-u.ac.jp/SnpDB/</ext-link>) and the
integrative Japanese Genome Variation Database (iJGVD) (<ext-link ext-link-type="uri" xlink:href="https://ijgvd.megabank.tohoku.ac.jp" xmlns:xlink="http://www.w3.org/1999/xlink">https://ijgvd.megabank.tohoku.ac.jp</ext-link>)<sup><xref ref-type="bibr" rid="bib60">60</xref></sup> with approximately the same frequency as that of our
cohort, and the Met138Ile variant was found in multiple Asian individuals in ExAC
(<xref ref-type="table" rid="tbl1">Table 1</xref>).</p>
<p>The effective sample size and statistical power was computed using the web browser
program, Genetic Power Calculator (<ext-link ext-link-type="uri" xlink:href="http://pngu.mgh.harvard.edu/~purcell/gpc/" xmlns:xlink="http://www.w3.org/1999/xlink">http://pngu.mgh.harvard.edu/~purcell/gpc/</ext-link>).<sup><xref ref-type="bibr" rid="bib61">61</xref></sup> For our sample set of cases (<italic>n</italic>=3227) and
controls (<italic>n</italic>=3827), we computed a statistical power of
&gt;80% using the following parameters: disease prevalence of 0.01;
observed rare-allele frequency of 0.0018; odds ratio for dominant effect of
⩾2.3; and type I error rate of 0.05. Differences in genotype distribution
between cases and controls were tested with one-sided, Fisher’s exact tests.
A significant association between neurodevelopmental disorders (SCZ and ASD) and
Ala55Thr (Odds ratio=8.3, <italic>P</italic>=0.020) was observed (<xref ref-type="table" rid="tbl2">Table 2</xref>; <xref ref-type="supplementary-material" rid="sup1">Supplementary Table
S1</xref>). The clinical features of the five SCZ and two ASD cases, and
the one healthy control case with CX3CR1-Ala55Thr are shown in the <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S2</xref>.</p>
</sec>
<sec>
<title>Modeling of the 3D structure of CX3CR1-Ala55Thr</title>
<p>These genetic findings indicated the possibility that the CX3CR1-Ala55Thr variant
might associate with the pathogenesis of SCZ and ASD. We therefore preformed 3D
structural modeling of CX3CR1 including a membrane, the CX3CR1 ligand fractalkine,
and a heterotrimeric G protein (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). As seen
for other GPCR proteins, the CX3CR1 model has seven transmembrane (TM) helices
that pass through the cell membrane, and a small amphipathic α-helix called
‘helix 8’ in the C-terminal cytoplasmic region. Helix 8 is reported to
be important for signal transduction and interacts with the heterotrimeric G
protein and other diverse signaling molecules.<sup><xref ref-type="bibr" rid="bib61">61</xref>, <xref ref-type="bibr" rid="bib62">62</xref></sup> Ala55 is located in
TM1; however, it interacts with the helix 8 and not with the membrane. Several
non-polar residues of TM1 and helix 8 form a hydrophobic core: Leu51, Val52, and
Ala55 of TM1, and Phe300, Tyr303, Leu304, and Leu307 of helix 8 (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). The variant of Ala to Thr in which residue 55
is changed from a hydrophobic (alanine) to a hydrophilic residue (threonine) may
weaken the hydrophobic interaction between TM1 and helix 8, and destabilize the
conformation of helix 8 (<xref ref-type="fig" rid="fig2">Figures 2b and c</xref>). This
conformational change of helix 8 may then disturb the interaction with Gα
and downstream signaling pathways.</p>
</sec>
<sec>
<title>Functional analysis of the effect of CX3CR1-Ala55Thr on Akt
phosphorylation</title>
<p>We then investigated the effect of CX3CR1-Ala55Thr on CX3CR1 signaling. We first
generated expression vectors encoding CX3CR1 WT or the Ala55Thr mutant conjugated
with mCherry, and assessed their subcellular localization in HEK293 cells. There
were no obvious differences in subcellular localization between CX3CR1 WT and its
Ala55Thr mutant (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). We then investigated the
effects of Ala55Thr mutation on CX3CR1 signaling in HEK293 cells. It is well
established that the chemokine fractalkine activates the Akt pathway through
CX3CR1.<sup><xref ref-type="bibr" rid="bib39">39</xref>, <xref ref-type="bibr" rid="bib41">41</xref>, <xref ref-type="bibr" rid="bib63">63</xref></sup> HEK293 cells were
used for the present study because it has been reported that the level of
fractalkine binding with non-transfected HEK293 cells is very low.<sup><xref ref-type="bibr" rid="bib64">64</xref></sup> Overexpression of CX3CR1 WT in HEK293 cells
increased the phosphorylation level of Akt in the presence of fractalkine.
However, treatment with fractalkine did not induce Akt phosphorylation when the
cells were transfected with the CX3CR1-Ala55Thr mutant (<xref ref-type="fig" rid="fig3">Figure
3b</xref>). These results suggest that CX3CR1-Ala55Thr mutation inhibits
fractalkine-CX3CR1 signaling.</p>
</sec>
</sec>
<sec>
<title>Discussion</title>
<p>Our results of the genetic association of the Ala55Thr variant in <italic>CX3CR1</italic>
with both SCZ and ASD; the conformational change in the CX3CR1-Ala55Thr mutant
compared with CX3CR1 WT that was predicted by <italic>in silico</italic> 3D structural
modeling; and the downregulation of fractalkine-CX3CR1 signaling by the Ala55Thr
mutant <italic>in vivo</italic> support the hypothesis that this variant in <italic>CX3CR1</italic>
might be a plausible candidate causal variant in SCZ and ASD etiopathologies. Rare
variants with a large effect may explain a part of the missing
heritability.<sup><xref ref-type="bibr" rid="bib9">9</xref></sup> In this regard, we
detected one condition-related SNV through targeted resequencing of coding exons in
<italic>CX3CR1</italic> for 562 Japanese SCZ or ASD patients and subsequent genetic
association analysis in a sample comprising 7054 unrelated individuals. A
statistically significant association was found between Ala55Thr and SCZ, ASD and
both phenotypes (odds ratio=7.2, 13.1 and 8.3, respectively) (<xref ref-type="table" rid="tbl2">Table 2;</xref>
<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref>). Inheritance for cases with
Ala55Thr was either from an unaffected father to son or of unknown origin (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>), suggesting variable penetrance.
This finding is consistent with recent genetic studies; deleterious alleles are
likely to be especially rare because of purifying selection.<sup><xref ref-type="bibr" rid="bib9">9</xref></sup> Inherited-truncating variants especially in genes that are
closely involved in neurodevelopment are highly enriched in patient
populations.<sup><xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib65">65</xref>, <xref ref-type="bibr" rid="bib66">66</xref>, <xref ref-type="bibr" rid="bib67">67</xref>, <xref ref-type="bibr" rid="bib68">68</xref></sup> Thus CX3CR1-Ala55Thr
could increase susceptibility to the development of a neuropsychiatric disorder.</p>
<p>Modeling of the 3D structure of the CX3CR1 WT and its Ala55Thr mutant suggested that
the Ala55Thr mutation might destabilize the hydrophobic interaction between TM1 and
helix 8. The canonical mechanism of signal transduction initiated by GPCRs involves
the activation of a heterotrimeric G protein by an agonist-occupied
receptor.<sup><xref ref-type="bibr" rid="bib60">60</xref>, <xref ref-type="bibr" rid="bib63">63</xref></sup> In addition to the seven transmembrane helices,
conformational dynamics of helix 8 in the cytoplasmic C terminus has been suggested
to have an important role in its intracellular signal transduction.<sup><xref ref-type="bibr" rid="bib61">61</xref>, <xref ref-type="bibr" rid="bib62">62</xref></sup> Functional
analysis using <italic>in vitro</italic> assays indicated that the Ala55Thr variant in CX3CR1
might decrease the fractalkine-CX3CR1 signaling. Its signaling impairment has been
reported to influence microglial function.<sup><xref ref-type="bibr" rid="bib69">69</xref>,
<xref ref-type="bibr" rid="bib70">70</xref></sup> On the basis of the complementary
expression of fractalkine on neurons and CX3CR1 on microglia, it has been proposed
that the neuron signaling to microglia is mediated through the CX3CR1
receptor.<sup><xref ref-type="bibr" rid="bib31">31</xref></sup> Fractalkine-CX3CR1
signaling might limit microglia toxicity through induction of PI3K/Akt and
ERK1/2 phosphorylation.<sup><xref ref-type="bibr" rid="bib45">45</xref>, <xref ref-type="bibr" rid="bib71">71</xref>, <xref ref-type="bibr" rid="bib72">72</xref>, <xref ref-type="bibr" rid="bib73">73</xref></sup> As there are no differences in fractalkine and
CX3CR1 expression in brain tissue between patients with and without neurodegenerative
diseases,<sup><xref ref-type="bibr" rid="bib69">69</xref></sup> it is conceivable that
functional change in fractalkine-CX3CR1 signaling could contribute to the
pathophysiology of neurodevelopmental disorders by modulating microglial
activation.</p>
<p>There are several limitations of this study. First, although the data presented here
support the hypothesis that rare variants in <italic>CX3CR1</italic> contribute to the
neurodevelopmental disorders of SCZ and ASD, it is clear that multiple pathways
regulate synapse connectivity in the brain, which account for complex genetic
influences on SCZ and ASD pathogenesis. Of note, the Ala55Thr variant in
<italic>CX3CR1</italic> was present in an extremely small fraction (&lt;0.5%) of
the tested patients with neurodevelopmental disorders. The idea of performing a study
that focuses on coding variants of a gene in terms of their contribution to a disease
has been supported by a recent finding that rare and low-frequency coding variants
contribute to the genetic architecture of a complex trait;<sup><xref ref-type="bibr" rid="bib11">11</xref></sup> however, the promoter, untranslated regions or intronic
regions of <italic>CX3CR1</italic> that our variation screening did not cover, also
potentially contain disease-associated regions. Second, regarding the
genotype–phenotype evaluations, we could neither fully explore the impact of
the novel variant nor monitor variant segregation due to limited access to the
detailed clinical phenotypes of patients and to lack of DNA from patient family
members. Although the father carrying CX3CR1-Ala55Thr had neither history of mental
disorders nor symptom causing clinically significant impairments in social,
occupational or other important areas of current functioning, possibility that the
father might present personality traits, which have been indicated as the
‘Broader Autism Phenotype’ still remains.<sup><xref ref-type="bibr" rid="bib74">74</xref></sup> Careful assessments of proband and family members will
provide insight into the underlying genetic mechanisms and determine the impact of
rare <italic>CX3CR1</italic> variants on psychopathology. Finally, we only demonstrated a
reduction in the Akt phosphorylation-mediated signaling by CX3CR1-Ala55Thr using
HEK293 cells. Additional factors produced by microglia may ameliorate the disturbed
function of CX3CR1 <italic>in vivo</italic>. Further analysis performed in microglia will be
needed to assess the exact molecular mechanisms and networks affected by
<italic>CX3CR1</italic> variants in SCZ and ASD.</p>
<p>In conclusion, individuals with the Ala55Thr variant of <italic>CX3CR1</italic> might
increase the susceptibility to developing the neurodevelopmental disorders such as
SCZ and ASD. To our knowledge, our findings provide the first genetic evidence in a
microglia-specific gene for association with neurodevelopmental disorders. A deeper
understanding of genetic risk factors and disease pathobiology may lead to major
health benefits through the development of methods for the prevention, diagnoses and
treatment of such diseases.</p>
</sec>
</body>
<back>
<ack>
<p>We are grateful to all the patients, their families, and control individuals who
contributed to this study. This work was supported by research grants from the Ministry
of Education, Culture, Sports, Science, and Technology of Japan; the Ministry of Health,
Labour, and Welfare of Japan; the Platform Project for Supporting in Drug Discovery and
Life Science Research (Platform for Drug Discovery, Informatics, and Structural Life
Science) from Japan Agency for Medical Research and Development (AMED); the Strategic
Research Program for Brain Sciences of AMED; the Brain Mapping by Integrated
Neurotechnologies for Disease Studies (Brain/MINDS) project of AMED; Grant-in-Aid
for Scientific Research on Innovative Areas ‘Glial assembly: a new regulatory
machinery of brain function and disorders’ and Innovative Areas
‘Comprehensive Brain Science Network’.</p>
</ack>
<fn-group>
<fn>
<p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies the paper on the
<italic>Translational Psychiatry</italic> website (http://www.nature.com/tp)</p>
</fn>
<fn fn-type="COI-statement">
<p>The authors declare no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<ref id="bib1">
<mixed-citation publication-type="journal">Rapoport J, Chavez A, Greenstein D, Addington A, Gogtay N. <article-title>Autism spectrum disorders and childhood-onset schizophrenia: clinical and
biological contributions to a relation revisited</article-title>. <source/>J Am Acad Child Adolesc Psychiatry
<year>2009</year>; <volume>48</volume>: <fpage>10</fpage>–18.<pub-id pub-id-type="pmid">19218893</pub-id></mixed-citation>
</ref>
<ref id="bib2">
<mixed-citation publication-type="journal">Sullivan PF, Daly MJ, O'Donovan M. <article-title>Genetic architectures of psychiatric disorders: the emerging picture and its
implications</article-title>. <source/>Nat Rev Genet
<year>2012</year>; <volume>13</volume>: <fpage>537</fpage>–551.<pub-id pub-id-type="pmid">22777127</pub-id></mixed-citation>
</ref>
<ref id="bib3">
<mixed-citation publication-type="journal">Sullivan PF, Magnusson C, Reichenberg A, Boman M, Dalman C, Davidson M et al. <article-title>Family history of schizophrenia and bipolar disorder as risk factors for
autism</article-title>. <source/>Arch Gen Psychiatry
<year>2012</year>; <volume>69</volume>: <fpage>1099</fpage>–1103.<pub-id pub-id-type="pmid">22752149</pub-id></mixed-citation>
</ref>
<ref id="bib4">
<mixed-citation publication-type="journal">Craddock N, Owen MJ. <article-title>The Kraepelinian dichotomy—going, going... but still not gone</article-title>. <source/>Br J Psychiatry
<year>2010</year>; <volume>196</volume>: <fpage>92</fpage>–95.<pub-id pub-id-type="pmid">20118450</pub-id></mixed-citation>
</ref>
<ref id="bib5">
<mixed-citation publication-type="journal">Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM et al. <article-title>Genetic relationship between five psychiatric disorders estimated from
genome-wide SNPs</article-title>. <source/>Nat Genet
<year>2013</year>; <volume>45</volume>: <fpage>984</fpage>–994.<pub-id pub-id-type="pmid">23933821</pub-id></mixed-citation>
</ref>
<ref id="bib6">
<mixed-citation publication-type="journal">Cross-Disorder Group of the Psychiatric Genomics Consortium. <article-title>Identification of risk loci with shared effects on five major psychiatric
disorders: a genome-wide analysis</article-title>. <source/>Lancet
<year>2013</year>; <volume>381</volume>: <fpage>1371</fpage>–1379.<pub-id pub-id-type="pmid">23453885</pub-id></mixed-citation>
</ref>
<ref id="bib7">
<mixed-citation publication-type="journal">Kryukov GV, Pennacchio LA, Sunyaev SR. <article-title>Most rare missense alleles are deleterious in humans: implications for complex
disease and association studies</article-title>. <source/>Am J Hum Genet
<year>2007</year>; <volume>80</volume>: <fpage>727</fpage>–739.<pub-id pub-id-type="pmid">17357078</pub-id></mixed-citation>
</ref>
<ref id="bib8">
<mixed-citation publication-type="journal">McClellan J, King MC. <article-title>Genetic heterogeneity in human disease</article-title>. <source/>Cell
<year>2010</year>; <volume>141</volume>: <fpage>210</fpage>–217.<pub-id pub-id-type="pmid">20403315</pub-id></mixed-citation>
</ref>
<ref id="bib9">
<mixed-citation publication-type="journal">Gibson G. <article-title>Rare and common variants: twenty arguments</article-title>. <source/>Nat Rev Genet
<year>2011</year>; <volume>13</volume>: <fpage>135</fpage>–145.</mixed-citation>
</ref>
<ref id="bib10">
<mixed-citation publication-type="journal">Zuk O, Schaffner SF, Samocha K, Do R, Hechter E, Kathiresan S et al. <article-title>Searching for missing heritability: designing rare variant association
studies</article-title>. <source/>Proc Natl Acad Sci USA
<year>2014</year>; <volume>111</volume>: <fpage>E455</fpage>–E464.<pub-id pub-id-type="pmid">24443550</pub-id></mixed-citation>
</ref>
<ref id="bib11">
<mixed-citation publication-type="journal">Marouli E, Graff M, Medina-Gomez C, Lo KS, Wood AR, Kjaer TR et al. <article-title>Rare and low-frequency coding variants alter human adult height</article-title>. <source/>Nature
<year>2017</year>; <volume>542</volume>: <fpage>186</fpage>–190.<pub-id pub-id-type="pmid">28146470</pub-id></mixed-citation>
</ref>
<ref id="bib12">
<mixed-citation publication-type="journal">Penzes P, Cahill ME, Jones KA, VanLeeuwen J-E, Woolfrey KM. <article-title>Dendritic spine pathology in neuropsychiatric disorders</article-title>. <source/>Nat Neurosci
<year>2011</year>; <volume>14</volume>: <fpage>285</fpage>–293.<pub-id pub-id-type="pmid">21346746</pub-id></mixed-citation>
</ref>
<ref id="bib13">
<mixed-citation publication-type="journal">De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE et al. <article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>. <source/>Nature
<year>2014</year>; <volume>515</volume>: <fpage>209</fpage>–215.<pub-id pub-id-type="pmid">25363760</pub-id></mixed-citation>
</ref>
<ref id="bib14">
<mixed-citation publication-type="journal">Kenny EM, Cormican P, Furlong S, Heron E, Kenny G, Fahey C et al. <article-title>Excess of rare novel loss-of-function variants in synaptic genes in
schizophrenia and autism spectrum disorders</article-title>. <source/>Mol Psychiatry
<year>2014</year>; <volume>19</volume>: <fpage>872</fpage>–879.<pub-id pub-id-type="pmid">24126926</pub-id></mixed-citation>
</ref>
<ref id="bib15">
<mixed-citation publication-type="journal">Hommer RE, Swedo SE. <article-title>Schizophrenia and autism-related disorders</article-title>. <source/>Schizophr Bull
<year>2015</year>; <volume>41</volume>: <fpage>313</fpage>–314.<pub-id pub-id-type="pmid">25634913</pub-id></mixed-citation>
</ref>
<ref id="bib16">
<mixed-citation publication-type="journal">Bourgeron T. <article-title>From the genetic architecture to synaptic plasticity in autism spectrum
disorder</article-title>. <source/>Nat Rev Neurosci
<year>2015</year>; <volume>16</volume>: <fpage>551</fpage>–563.<pub-id pub-id-type="pmid">26289574</pub-id></mixed-citation>
</ref>
<ref id="bib17">
<mixed-citation publication-type="journal">Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S et al. <article-title>ATP mediates rapid microglial response to local brain injury <italic>in
vivo</italic></article-title>. <source/>Nat Neurosci
<year>2005</year>; <volume>8</volume>: <fpage>752</fpage>–758.<pub-id pub-id-type="pmid">15895084</pub-id></mixed-citation>
</ref>
<ref id="bib18">
<mixed-citation publication-type="journal">Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. <article-title>Resting microglia directly monitor the functional state of synapses <italic>in
vivo</italic> and determine the fate of ischemic terminals</article-title>. <source/>J Neurosci
<year>2009</year>; <volume>29</volume>: <fpage>3974</fpage>–3980.<pub-id pub-id-type="pmid">19339593</pub-id></mixed-citation>
</ref>
<ref id="bib19">
<mixed-citation publication-type="journal">Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P et al. <article-title>Synaptic pruning by microglia is necessary for normal brain development</article-title>. <source/>Science
<year>2011</year>; <volume>333</volume>: <fpage>1456</fpage>–1458.<pub-id pub-id-type="pmid">21778362</pub-id></mixed-citation>
</ref>
<ref id="bib20">
<mixed-citation publication-type="journal">Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R et al. <article-title>Microglia sculpt postnatal neural circuits in an activity and
complement-dependent manner</article-title>. <source/>Neuron
<year>2012</year>; <volume>74</volume>: <fpage>691</fpage>–705.<pub-id pub-id-type="pmid">22632727</pub-id></mixed-citation>
</ref>
<ref id="bib21">
<mixed-citation publication-type="journal">Ueno M, Fujita Y, Tanaka T, Nakamura Y, Kikuta J, Ishii M et al. <article-title>Layer V cortical neurons require microglial support for survival during
postnatal development</article-title>. <source/>Nat Neurosci
<year>2013</year>; <volume>16</volume>: <fpage>543</fpage>–551.<pub-id pub-id-type="pmid">23525041</pub-id></mixed-citation>
</ref>
<ref id="bib22">
<mixed-citation publication-type="journal">Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. <article-title>Neuroinflammation and psychiatric illness</article-title>. <source/>J Neuroinflammation
<year>2013</year>; <volume>10</volume>: <fpage>43</fpage>.<pub-id pub-id-type="pmid">23547920</pub-id></mixed-citation>
</ref>
<ref id="bib23">
<mixed-citation publication-type="journal">Prinz M, Priller J. <article-title>Microglia and brain macrophages in the molecular age: from origin to
neuropsychiatric disease</article-title>. <source/>Nat Rev Neurosci
<year>2014</year>; <volume>15</volume>: <fpage>300</fpage>–312.<pub-id pub-id-type="pmid">24713688</pub-id></mixed-citation>
</ref>
<ref id="bib24">
<mixed-citation publication-type="journal">Chung WS, Welsh CA, Barres BA, Stevens B. <article-title>Do glia drive synaptic and cognitive impairment in disease</article-title>? <source/>Nat Neurosci
<year>2015</year>; <volume>18</volume>: <fpage>1539</fpage>–1545.<pub-id pub-id-type="pmid">26505565</pub-id></mixed-citation>
</ref>
<ref id="bib25">
<mixed-citation publication-type="journal">Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N et al. <article-title>Schizophrenia risk from complex variation of complement component 4</article-title>. <source/>Nature
<year>2016</year>; <volume>530</volume>: <fpage>177</fpage>–183.<pub-id pub-id-type="pmid">26814963</pub-id></mixed-citation>
</ref>
<ref id="bib26">
<mixed-citation publication-type="journal">van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E et al. <article-title>Microglia activation in recent-onset schizophrenia: a quantitative
(R)-[11C]PK11195 positron emission tomography study</article-title>. <source/>Biol Psychiatry
<year>2008</year>; <volume>64</volume>: <fpage>820</fpage>–822.<pub-id pub-id-type="pmid">18534557</pub-id></mixed-citation>
</ref>
<ref id="bib27">
<mixed-citation publication-type="journal">Goudriaan A, de Leeuw C, Ripke S, Hultman CM, Sklar P, Sullivan PF et al. <article-title>Specific glial functions contribute to schizophrenia susceptibility</article-title>. <source/>Schizophr Bull
<year>2014</year>; <volume>40</volume>: <fpage>925</fpage>–935.<pub-id pub-id-type="pmid">23956119</pub-id></mixed-citation>
</ref>
<ref id="bib28">
<mixed-citation publication-type="journal">Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K et al. <article-title>Microglial activation in young adults with autism spectrum disorder</article-title>. <source/>JAMA Psychiatry
<year>2013</year>; <volume>70</volume>: <fpage>49</fpage>–58.<pub-id pub-id-type="pmid">23404112</pub-id></mixed-citation>
</ref>
<ref id="bib29">
<mixed-citation publication-type="journal">Bergon A, Belzeaux R, Comte M, Pelletier F, Herve M, Gardiner EJ et al. <article-title>CX3CR1 is dysregulated in blood and brain from schizophrenia patients</article-title>. <source/>Schizophr Res
<year>2015</year>; <volume>168</volume>: <fpage>434</fpage>–443.<pub-id pub-id-type="pmid">26285829</pub-id></mixed-citation>
</ref>
<ref id="bib30">
<mixed-citation publication-type="journal">Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S et al. <article-title>Transcriptomic analysis of autistic brain reveals convergent molecular
pathology</article-title>. <source/>Nature
<year>2011</year>; <volume>474</volume>: <fpage>380</fpage>–384.<pub-id pub-id-type="pmid">21614001</pub-id></mixed-citation>
</ref>
<ref id="bib31">
<mixed-citation publication-type="journal">Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK et al. <article-title>Role for neuronally derived fractalkine in mediating interactions between
neurons and CX3CR1-expressing microglia</article-title>. <source/>Proc Natl Acad Sci USA
<year>1998</year>; <volume>95</volume>: <fpage>10896</fpage>–10901.<pub-id pub-id-type="pmid">9724801</pub-id></mixed-citation>
</ref>
<ref id="bib32">
<mixed-citation publication-type="journal">Tremblay ME, Lowery RL, Majewska AK. <article-title>Microglial interactions with synapses are modulated by visual
experience</article-title>. <source/>PLoS Biol
<year>2010</year>; <volume>8</volume>: <fpage>e1000527</fpage>.<pub-id pub-id-type="pmid">21072242</pub-id></mixed-citation>
</ref>
<ref id="bib33">
<mixed-citation publication-type="journal">Limatola C, Ransohoff RM. <article-title>Modulating neurotoxicity through CX3CL1/CX3CR1 signaling</article-title>. <source/>Front Cell Neurosci
<year>2014</year>; <volume>8</volume>: <fpage>229</fpage>.<pub-id pub-id-type="pmid">25152714</pub-id></mixed-citation>
</ref>
<ref id="bib34">
<mixed-citation publication-type="journal">Zhan Y, Paolicelli RC, Sforazzini F, Weinhard L, Bolasco G, Pagani F et al. <article-title>Deficient neuron-microglia signaling results in impaired functional brain
connectivity and social behavior</article-title>. <source/>Nat Neurosci
<year>2014</year>; <volume>17</volume>: <fpage>400</fpage>–406.<pub-id pub-id-type="pmid">24487234</pub-id></mixed-citation>
</ref>
<ref id="bib35">
<mixed-citation publication-type="journal">Sophie F, Laurence M, Dominique C, Céline V, Emmanuelle G, Brigitte A et al. <article-title>Rapid progression to AIDS in HIV+ individuals with a structural variant of
the chemokine receptor CX3CR1</article-title>. <source/>Science
<year>2000</year>; <volume>287</volume>: <fpage>2274</fpage>–2277.<pub-id pub-id-type="pmid">10731151</pub-id></mixed-citation>
</ref>
<ref id="bib36">
<mixed-citation publication-type="journal">Arli B, Irkec C, Menevse S, Yilmaz A, Alp E. <article-title>Fractalkine gene receptor polymorphism in patients with multiple
sclerosis</article-title>. <source/>Int J Neurosci
<year>2013</year>; <volume>123</volume>: <fpage>31</fpage>–37.<pub-id pub-id-type="pmid">22916723</pub-id></mixed-citation>
</ref>
<ref id="bib37">
<mixed-citation publication-type="journal">Lopez-Lopez A, Gamez J, Syriani E, Morales M, Salvado M, Rodriguez MJ et al. <article-title>CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral
sclerosis</article-title>. <source/>PLoS ONE
<year>2014</year>; <volume>9</volume>: <fpage>e96528</fpage>.<pub-id pub-id-type="pmid">24806473</pub-id></mixed-citation>
</ref>
<ref id="bib38">
<mixed-citation publication-type="journal">Tuo J, Smith BC, Bojanowski CM, Meleth AD, Gery I, Csaky KG et al. <article-title>The involvement of sequence variation and expression of CX3CR1 in the
pathogenesis of age-related macular degeneration</article-title>. <source/>FASEB J
<year>2004</year>; <volume>18</volume>: <fpage>1297</fpage>–1299.<pub-id pub-id-type="pmid">15208270</pub-id></mixed-citation>
</ref>
<ref id="bib39">
<mixed-citation publication-type="journal">Moatti D, Faure S, Fumeron F, Amara Mel-W, Seknadji P, McDermott DH et al. <article-title>Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for
coronary artery disease</article-title>. <source/>Blood
<year>2001</year>; <volume>97</volume>: <fpage>1925</fpage>–1928.<pub-id pub-id-type="pmid">11264153</pub-id></mixed-citation>
</ref>
<ref id="bib40">
<mixed-citation publication-type="journal">Lee S, Abecasis GR, Boehnke M, Lin X. <article-title>Rare-variant association analysis: study designs and statistical tests</article-title>. <source/>Am J Hum Genet
<year>2014</year>; <volume>95</volume>: <fpage>5</fpage>–23.<pub-id pub-id-type="pmid">24995866</pub-id></mixed-citation>
</ref>
<ref id="bib41">
<mixed-citation publication-type="journal">Heilker R, Wolff M, Tautermann CS, Bieler M. <article-title>G-protein-coupled receptor-focused drug discovery using a target class platform
approach</article-title>. <source/>Drug Discov Today
<year>2009</year>; <volume>14</volume>: <fpage>231</fpage>–240.<pub-id pub-id-type="pmid">19121411</pub-id></mixed-citation>
</ref>
<ref id="bib42">
<mixed-citation publication-type="journal">Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ. <article-title>The chemokine fractalkine inhibits Fas-mediated cell death of brain
microglia</article-title>. <source/>J Immunol
<year>2000</year>; <volume>165</volume>: <fpage>397</fpage>–403.<pub-id pub-id-type="pmid">10861077</pub-id></mixed-citation>
</ref>
<ref id="bib43">
<mixed-citation publication-type="journal">Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Feng L et al. <article-title>Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent
inflammatory signals induces aortic smooth muscle cell proliferation through an
autocrine pathway</article-title>. <source/>Biochem J
<year>2003</year>; <volume>373</volume>: <fpage>547</fpage>–558.<pub-id pub-id-type="pmid">12729461</pub-id></mixed-citation>
</ref>
<ref id="bib44">
<mixed-citation publication-type="journal">Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM et al. <article-title>Control of microglial neurotoxicity by the fractalkine receptor</article-title>. <source/>Nat Neurosci
<year>2006</year>; <volume>9</volume>: <fpage>917</fpage>–924.<pub-id pub-id-type="pmid">16732273</pub-id></mixed-citation>
</ref>
<ref id="bib45">
<mixed-citation publication-type="journal">Lee SJ, Namkoong S, Kim YM, Kim CK, Lee H, Ha KS et al. <article-title>Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and
PI3K/Akt/eNOS-dependent signal pathways</article-title>. <source/>Am J Physiol Heart Circ Physiol
<year>2006</year>; <volume>291</volume>: <fpage>H2836</fpage>–H2846.<pub-id pub-id-type="pmid">16877565</pub-id></mixed-citation>
</ref>
<ref id="bib46">
<mixed-citation publication-type="journal">Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E et al. <article-title>CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell
survival</article-title>. <source/>Blood
<year>2009</year>; <volume>113</volume>: <fpage>963</fpage>–972.<pub-id pub-id-type="pmid">18971423</pub-id></mixed-citation>
</ref>
<ref id="bib47">
<mixed-citation publication-type="journal">Nagasaki M, Yasuda J, Katsuoka F, Nariai N, Kojima K, Kawai Y et al. <article-title>Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese
individuals</article-title>. <source/>Nat Commun
<year>2015</year>; <volume>6</volume>: <fpage>8018</fpage>.<pub-id pub-id-type="pmid">26292667</pub-id></mixed-citation>
</ref>
<ref id="bib48">
<mixed-citation publication-type="journal">Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. <article-title>A method and server for predicting damaging missense mutations</article-title>. <source/>Nat Methods
<year>2010</year>; <volume>7</volume>: <fpage>248</fpage>–249.<pub-id pub-id-type="pmid">20354512</pub-id></mixed-citation>
</ref>
<ref id="bib49">
<mixed-citation publication-type="journal">Schwarz JM, Cooper DN, Schuelke M, Seelow D. <article-title>MutationTaster2: mutation prediction for the deep-sequencing age</article-title>. <source/>Nat Methods
<year>2014</year>; <volume>11</volume>: <fpage>361</fpage>–362.<pub-id pub-id-type="pmid">24681721</pub-id></mixed-citation>
</ref>
<ref id="bib50">
<mixed-citation publication-type="journal">Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM et al. <article-title>ClinVar: public archive of relationships among sequence variation and human
phenotype</article-title>. <source/>Nucleic Acids Res
<year>2014</year>; <volume>42</volume>: <fpage>D980</fpage>–D985.<pub-id pub-id-type="pmid">24234437</pub-id></mixed-citation>
</ref>
<ref id="bib51">
<mixed-citation publication-type="journal">Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D et al. <article-title>DECIPHER: database of chromosomal imbalance and phenotype in humans using
ensembl resources</article-title>. <source/>Am J Hum Genet
<year>2009</year>; <volume>84</volume>: <fpage>524</fpage>–533.<pub-id pub-id-type="pmid">19344873</pub-id></mixed-citation>
</ref>
<ref id="bib52">
<mixed-citation publication-type="journal">Purcell S, Cherny SS, Sham PC. <article-title>Genetic power calculator: design of linkage and association genetic mapping
studies of complex traits</article-title>. <source/>Bioinformatics
<year>2003</year>; <volume>19</volume>: <fpage>149</fpage>–150.<pub-id pub-id-type="pmid">12499305</pub-id></mixed-citation>
</ref>
<ref id="bib53">
<mixed-citation publication-type="journal">Zheng Y, Qin L, Zacarias NV, de Vries H, Han GW, Gustavsson M et al. <article-title>Structure of CC chemokine receptor 2 with orthosteric and allosteric
antagonists</article-title>. <source/>Nature
<year>2016</year>; <volume>540</volume>: <fpage>458</fpage>–461.<pub-id pub-id-type="pmid">27926736</pub-id></mixed-citation>
</ref>
<ref id="bib54">
<mixed-citation publication-type="journal">Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS et al. <article-title>Crystal structure of the beta2 adrenergic receptor–Gs protein
complex</article-title>. <source/>Nature
<year>2011</year>; <volume>477</volume>: <fpage>549</fpage>–555.<pub-id pub-id-type="pmid">21772288</pub-id></mixed-citation>
</ref>
<ref id="bib55">
<mixed-citation publication-type="journal">Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W et al. <article-title>Gapped BLAST and PSI-BLAST: a new generation of protein database search
programs</article-title>. <source/>Nucleic Acids Res
<year>1997</year>; <volume>25</volume>: <fpage>3389</fpage>–3402.<pub-id pub-id-type="pmid">9254694</pub-id></mixed-citation>
</ref>
<ref id="bib56">
<mixed-citation publication-type="journal">Kawabata T. <article-title>HOMCOS: an updated server to search and model complex 3D structures</article-title>. <source/>J Struct Funct Genomics
<year>2016</year>; <volume>17</volume>: <fpage>83</fpage>–99.<pub-id pub-id-type="pmid">27522608</pub-id></mixed-citation>
</ref>
<ref id="bib57">
<mixed-citation publication-type="journal">Sali A, Blundell T. <article-title>Comparative protein modelling by satisfaction of spatial restraints</article-title>. <source/>J Mol Biol
<year>1993</year>; <volume>234</volume>: <fpage>779</fpage>–815.<pub-id pub-id-type="pmid">8254673</pub-id></mixed-citation>
</ref>
<ref id="bib58">
<mixed-citation publication-type="journal">Kawabata T, Nishikawa K. <article-title>Protein structure comparison using the markov transition model of
evolution</article-title>. <source/>Proteins
<year>2000</year>; <volume>41</volume>: <fpage>108</fpage>–122.<pub-id pub-id-type="pmid">10944398</pub-id></mixed-citation>
</ref>
<ref id="bib59">
<mixed-citation publication-type="journal">Wada M, Kanamori E, Nakamura H, Fukunishi Y. <article-title>Selection of in silico drug screening results for G-protein-coupled receptors by
using universal active probes</article-title>. <source/>J Chem Inf Model
<year>2011</year>; <volume>51</volume>: <fpage>2398</fpage>–2407.<pub-id pub-id-type="pmid">21848279</pub-id></mixed-citation>
</ref>
<ref id="bib60">
<mixed-citation publication-type="journal">Burg JS, Ingram JR, Venkatakrishnan A, Jude KM, Dukkipati A, Feinberg EN et al. <article-title>Structural basis for chemokine recognition and activation of a viral G
protein-coupled receptor</article-title>. <source/>Science
<year>2015</year>; <volume>347</volume>: <fpage>1113</fpage>–1117.<pub-id pub-id-type="pmid">25745166</pub-id></mixed-citation>
</ref>
<ref id="bib61">
<mixed-citation publication-type="journal">Huynh J, Thomas WG, Aguilar M-I, Pattenden LK. <article-title>Role of helix 8 in G protein-coupled receptors based on structure–function
studies on the type 1 angiotensin receptor</article-title>. <source/>Mol Cell Endocrinol
<year>2009</year>; <volume>302</volume>: <fpage>118</fpage>–127.<pub-id pub-id-type="pmid">19418628</pub-id></mixed-citation>
</ref>
<ref id="bib62">
<mixed-citation publication-type="journal">Sato T, Kawasaki T, Mine S, Matsumura H. <article-title>Functional role of the C-terminal amphipathic helix 8 of olfactory receptors and
other G protein-coupled receptors</article-title>. <source/>Int J Mol Sci
<year>2016</year>; <volume>17</volume>: <fpage>1930</fpage>.</mixed-citation>
</ref>
<ref id="bib63">
<mixed-citation publication-type="journal">Nishimura A, Kitano K, Takasaki J, Taniguchi M, Mizuno N, Tago K et al. <article-title>Structural basis for the specific inhibition of heterotrimeric Gq protein by a
small molecule</article-title>. <source/>Proc Natl Acad Sci USA
<year>2010</year>; <volume>107</volume>: <fpage>13666</fpage>–13671.<pub-id pub-id-type="pmid">20639466</pub-id></mixed-citation>
</ref>
<ref id="bib64">
<mixed-citation publication-type="journal">Cybulsky MI, Hegele RA. <article-title>The fractalkine receptor CX3CR1 is a key mediator of atherogenesis</article-title>. <source/>J Clin Invest
<year>2003</year>; <volume>111</volume>: <fpage>1118</fpage>–1120.<pub-id pub-id-type="pmid">12697729</pub-id></mixed-citation>
</ref>
<ref id="bib65">
<mixed-citation publication-type="journal">Mowry BJ, Gratten J. <article-title>The emerging spectrum of allelic variation in schizophrenia: current evidence
and strategies for the identification and functional characterization of common and
rare variants</article-title>. <source/>Mol Psychiatry
<year>2013</year>; <volume>18</volume>: <fpage>38</fpage>–52.<pub-id pub-id-type="pmid">22547114</pub-id></mixed-citation>
</ref>
<ref id="bib66">
<mixed-citation publication-type="journal">Hoischen A, Krumm N, Eichler EE. <article-title>Prioritization of neurodevelopmental disease genes by discovery of new
mutations</article-title>. <source/>Nat Neurosci
<year>2014</year>; <volume>17</volume>: <fpage>764</fpage>–772.<pub-id pub-id-type="pmid">24866042</pub-id></mixed-citation>
</ref>
<ref id="bib67">
<mixed-citation publication-type="journal">Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P et al. <article-title>A polygenic burden of rare disruptive mutations in schizophrenia</article-title>. <source/>Nature
<year>2014</year>; <volume>506</volume>: <fpage>185</fpage>–190.<pub-id pub-id-type="pmid">24463508</pub-id></mixed-citation>
</ref>
<ref id="bib68">
<mixed-citation publication-type="journal">Krumm N, Turner TN, Baker C, Vives L, Mohajeri K, Witherspoon K et al. <article-title>Excess of rare, inherited truncating mutations in autism</article-title>. <source/>Nat Genet
<year>2015</year>; <volume>47</volume>: <fpage>582</fpage>–588.<pub-id pub-id-type="pmid">25961944</pub-id></mixed-citation>
</ref>
<ref id="bib69">
<mixed-citation publication-type="journal">Hulshof S, van Haastert E, Kuipers H, van den Elsen P, De Groot C, van der Valk P et al. <article-title>CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control
versus multiple sclerosis</article-title>. <source/>J Neuropathol Exp Neurol
<year>2003</year>; <volume>62</volume>: <fpage>899</fpage>–907.<pub-id pub-id-type="pmid">14533779</pub-id></mixed-citation>
</ref>
<ref id="bib70">
<mixed-citation publication-type="journal">Wolf Y, Yona S, Kim K-W, Jung S. <article-title>Microglia, seen from the CX3CR1 angle</article-title>. <source/>Front Cell Neurosci
<year>2013</year>; <volume>7</volume>: <fpage>26</fpage>.<pub-id pub-id-type="pmid">23507975</pub-id></mixed-citation>
</ref>
<ref id="bib71">
<mixed-citation publication-type="journal">Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB. <article-title>Characterization of fractalkine in rat brain cells: migratory and activation
signals for CX3CR-1-expressing microglia</article-title>. <source/>J Immunol
<year>1999</year>; <volume>163</volume>: <fpage>1628</fpage>–1635.<pub-id pub-id-type="pmid">10415068</pub-id></mixed-citation>
</ref>
<ref id="bib72">
<mixed-citation publication-type="journal">Shuzhen C, Defang L, Wolfgang JS, Jeffrey KH. <article-title>TGF-β1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated
signaling in rat microglia</article-title>. <source/>J Neuroimmunol
<year>2002</year>; <volume>133</volume>: <fpage>46</fpage>–55.<pub-id pub-id-type="pmid">12446007</pub-id></mixed-citation>
</ref>
<ref id="bib73">
<mixed-citation publication-type="journal">Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P et al. <article-title>CX3CR1 protein signaling modulates microglial activation and protects against
plaque-independent cognitive deficits in a mouse model of Alzheimer disease</article-title>. <source/>J Biol Chem
<year>2011</year>; <volume>286</volume>: <fpage>32713</fpage>–32722.<pub-id pub-id-type="pmid">21771791</pub-id></mixed-citation>
</ref>
<ref id="bib74">
<mixed-citation publication-type="journal">Billeci L, Calderoni S, Conti E, Gesi C, Carmassi C, Dell’Osso L et al. <article-title>The broad autism (Endo)phenotype: neurostructural and neurofunctional correlates
in parents of individuals with autism spectrum disorders</article-title>. <source/>Front Neurosci
<year>2016</year>; <volume>10</volume>: <fpage>346</fpage>.<pub-id pub-id-type="pmid">27499732</pub-id></mixed-citation>
</ref>
</ref-list>
<sec id="sup1" sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="xob1">
<label>Supplementary Information</label>
<media xlink:href="tp2017173x1.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</back>
<floats-group>
<fig id="fig1">
<label>Figure 1</label>
<caption>
<p>Genomic locations of the variants in <italic>CX3CR1</italic> detected in this study.
<italic>Note</italic>: Localization of a protein domain is based on the human protein
reference database (<ext-link ext-link-type="uri" xlink:href="http://www.hprd.org/index.html" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.hprd.org/index.html</ext-link>) (HPRD). Genomic position is based on
NCBI builds GRCh38 (Ensembl Transcript ID ENST000000399220). Amino acid position
is based on the NCBI reference sequences NP_001328.1 and DDBJ DRA004490. UTR,
untranslated regions.</p>
</caption>
<graphic xlink:href="tp2017173f1" xmlns:xlink="http://www.w3.org/1999/xlink"></graphic>
</fig>
<fig id="fig2">
<label>Figure 2</label>
<caption>
<p>3D model of the structure of the CX3CR1-Ala55Thr mutant. (<bold>a</bold>) 3D model of
the structure of CX3CR1, fractalkine, a heterotrimeric G protein (Gα,
Gβ, Gγ) and the cellular membrane. Three CX3CR1-mutated sites (Ala55,
Gly112, Met138) are indicated in dotted black circles. (<bold>b</bold>) Enlarged view of
the 55th residue of wild-type CX3CR1. (<bold>c</bold>) Enlarged view of the 55th residue
of the CX3CR1-Ala55Thr mutant.</p>
</caption>
<graphic xlink:href="tp2017173f2" xmlns:xlink="http://www.w3.org/1999/xlink"></graphic>
</fig>
<fig id="fig3">
<label>Figure 3</label>
<caption>
<p>Effect of CX3CR1-Ala55Thr on Akt phosphorylation-mediated signaling. (<bold>a</bold>)
Subcellular localization of CX3CR1 wild-type (WT) or its Ala55Thr mutant.
mCherry-fused CX3CR1 WT or mutant-expressing vectors were transfected into HEK293
cells and cultured for 36 h before immunofluorescent analysis. DIC,
differential interference contrast. Scale bar, 25 μm. (<bold>b</bold>) Ala55Thr
mutation in CX3CR1 inhibits Akt phosphorylation upon fractalkine (FKN) treatment.
HEK293 cells transfected with an mCherry-conjugated CX3CR1 WT or
Ala55Thr-expressing vector were cultured for 36 h, and then the cells were
stimulated with the CX3CR1 ligand fractalkine for 15 min. Cell lysates were
analyzed by western blotting using the indicated antibodies. The data are
expressed as means±s.e.m. and statistical significance was tested with
analysis of variance followed by Tukey–Kramer’s multiple comparison
test. **<italic>P</italic>&lt;0.01, *<italic>P</italic>&lt;0.05.
<italic>n</italic>=5.</p>
</caption>
<graphic xlink:href="tp2017173f3" xmlns:xlink="http://www.w3.org/1999/xlink"></graphic>
</fig>
<table-wrap id="tbl1">
<label>Table 1</label>
<caption>
<title>
<italic>CX3CR1</italic> variants identified in this study</title>
</caption>
<table border="1" frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead valign="bottom">
<tr>
<th align="left" charoff="50" valign="top">
<italic>Chr</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>Position (dbSNPID)</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>Transcript variant</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>Amino acid variant</italic>
</th>
<th align="center" charoff="50" valign="top"><italic>SCZ (</italic>n=<italic>370)</italic></th>
<th align="center" charoff="50" valign="top"><italic>ASD (</italic>n=<italic>192)</italic></th>
<th align="center" charoff="50" valign="top">
<italic>Our cohort</italic>
<xref ref-type="fn" rid="t1-fn2">a</xref>
<italic>MAF</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>HGVD</italic>
<xref ref-type="fn" rid="t1-fn2">a</xref>
<italic>MAF</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>iJGVD</italic>
<xref ref-type="fn" rid="t1-fn2">a</xref>
<italic>MAF</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>ExAC (Asian)</italic>
<xref ref-type="fn" rid="t1-fn2">a</xref>
<italic>MAF</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>ExAC (all)</italic>
<xref ref-type="fn" rid="t1-fn2">a</xref>
<italic>MAF</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>1000 Genomes</italic>
<xref ref-type="fn" rid="t1-fn2">a</xref>
<italic>MAF</italic>
</th>
<th align="center" charoff="50" colspan="2" valign="top">In silico
<italic>analysis</italic><hr/></th>
</tr>
<tr>
<th align="left" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top">
<italic>PolyPhen-2</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>MutationTaster</italic>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" charoff="50" valign="top">3</td>
<td align="center" charoff="50" valign="top">39266096 
(rs758302878)</td>
<td align="center" charoff="50" valign="top">c.414G&gt;T</td>
<td align="center" charoff="50" valign="top">Met138Ile</td>
<td align="center" charoff="50" valign="top">1F</td>
<td align="center" charoff="50" valign="top">—</td>
<td align="center" charoff="50" valign="top">1/1122
8.9 ×
10<sup>−4</sup></td>
<td align="center" charoff="50" valign="top">—</td>
<td align="center" charoff="50" valign="top">—</td>
<td align="center" charoff="50" valign="top">6/8626
7 ×
10<sup>−4</sup></td>
<td align="center" charoff="50" valign="top">6/120 720
5 ×
10<sup>−5</sup></td>
<td align="center" charoff="50" valign="top">—</td>
<td align="left" charoff="50" valign="top">Benign</td>
<td align="left" charoff="50" valign="top">Disease causing</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">3</td>
<td align="center" charoff="50" valign="top">39266175
(rs201442030)</td>
<td align="center" charoff="50" valign="top">c.335G&gt;C</td>
<td align="center" charoff="50" valign="top">Gly112Ala</td>
<td align="center" charoff="50" valign="top">1F, 1M</td>
<td align="center" charoff="50" valign="top">2M</td>
<td align="center" charoff="50" valign="top">4/1112
3.6 ×
10<sup>−3</sup></td>
<td align="center" charoff="50" valign="top">2/1102
1.8 ×
10<sup>−3</sup></td>
<td align="center" charoff="50" valign="top">6/4084
1.5 ×
10<sup>−3</sup></td>
<td align="center" charoff="50" valign="top">28/8624
3.2 ×
10<sup>−3</sup></td>
<td align="center" charoff="50" valign="top">36/120 712
3 ×
10<sup>−4</sup></td>
<td align="center" charoff="50" valign="top">1/1008
1 ×
10<sup>−3</sup></td>
<td align="left" charoff="50" valign="top">Probably
Damaging</td>
<td align="left" charoff="50" valign="top">Polymorphism</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">3</td>
<td align="center" charoff="50" valign="top">39266347
(rs750585901)</td>
<td align="center" charoff="50" valign="top">c.163G&gt;A</td>
<td align="center" charoff="50" valign="top">Ala55Thr</td>
<td align="center" charoff="50" valign="top">1M</td>
<td align="center" charoff="50" valign="top">1M</td>
<td align="center" charoff="50" valign="top">2/1122
3.6 ×
10<sup>−3</sup></td>
<td align="center" charoff="50" valign="top">—</td>
<td align="center" charoff="50" valign="top">1/4076
2.5 ×
10<sup>−4</sup></td>
<td align="center" charoff="50" valign="top">1/8626
1.2 ×
10<sup>−4</sup></td>
<td align="center" charoff="50" valign="top">1/120 768
8.3 ×
10<sup>−6</sup></td>
<td align="center" charoff="50" valign="top">—</td>
<td align="left" charoff="50" valign="top">Benign</td>
<td align="left" charoff="50" valign="top">Disease causing</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t1-fn1">
<p>Abbreviations: 1000 Genomes, the 1000 Genomes Project (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.1000genomes.org</ext-link>); ASD, autism spectrum disorders;
Chr, chromosome; dbSNP, dbSNP build 149 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.ncbi.nlm.nih.gov/projects/SNP/</ext-link>); ExAC, Exome
Aggregation Consortium (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://exac.broadinstitute.org</ext-link>); F, female; HGVD, the Human
Genetic Variation Database (<ext-link ext-link-type="uri" xlink:href="http://www.genome.med.kyoto-u.ac.jp/SnpDB/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.genome.med.kyoto-u.ac.jp/SnpDB/</ext-link>); iJGVD, the
integrative Japanese Genome Variation Database (<ext-link ext-link-type="uri" xlink:href="https://ijgvd.megabank.tohoku.ac.jp" xmlns:xlink="http://www.w3.org/1999/xlink">https://ijgvd.megabank.tohoku.ac.jp</ext-link>); M, male; MAF, minor
allele frequency; SCZ, schizophrenia.</p>
</fn>
<fn id="t1-fn2">
<label>a</label>
<p>Minor allele count/total allele count.</p>
</fn>
<fn id="t1-fn3">
<p><italic>Note</italic>: Genomic position based on NCBI builds GRCh38 (Ensembl
Transcript ID ENST000000399220). Amino acid position is based on NCBI
reference sequence NP_001328.1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tbl2">
<label>Table 2</label>
<caption>
<title>Genetic association analysis of CX3CR1-Ala55Thr</title>
</caption>
<table border="1" frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead valign="bottom">
<tr>
<th align="left" charoff="50" valign="top">
<italic>Exon</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>Ref</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>Val</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>Position</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>Variant</italic>
</th>
<th align="center" charoff="50" colspan="4" valign="top">
<italic>Case (SCZ+ASD)</italic>
<hr/></th>
<th align="center" charoff="50" colspan="2" valign="top">
<italic>Control</italic>
<hr/></th>
</tr>
<tr>
<th align="left" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top"> </th>
<th align="center" charoff="50" valign="top">
<italic>Allele count</italic>
<xref ref-type="fn" rid="t2-fn2">a</xref>
</th>
<th align="center" charoff="50" valign="top">
<italic>MAF</italic>
</th>
<th align="center" charoff="50" valign="top">
<italic>Odds ratio</italic>
</th>
<th align="center" charoff="50" valign="top">P<italic>-value</italic><xref ref-type="fn" rid="t2-fn3">b</xref></th>
<th align="center" charoff="50" valign="top">
<italic>Allele count</italic>
<xref ref-type="fn" rid="t2-fn2">a</xref>
</th>
<th align="center" charoff="50" valign="top">
<italic>MAF</italic>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" charoff="50" valign="top">2</td>
<td align="center" charoff="50" valign="top">G</td>
<td align="center" charoff="50" valign="top">A</td>
<td align="center" charoff="50" valign="top">3:39266347</td>
<td align="center" charoff="50" valign="top">p.Ala55Thr</td>
<td align="center" charoff="50" valign="top">7/6454</td>
<td align="center" charoff="50" valign="top">0.0011</td>
<td align="center" charoff="50" valign="top">8.3 (1.33–inf)</td>
<td align="center" charoff="50" valign="top">0.020</td>
<td align="center" charoff="50" valign="top">1/7652</td>
<td align="center" charoff="50" valign="top">0.00013</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t2-fn1">
<p>Abbreviations: ASD, autism spectrum disorders; MAF, minor allele frequency;
Ref, reference; SCZ, schizophrenia; Val, variant.</p>
</fn>
<fn id="t2-fn2">
<label>a</label>
<p>Minor allele/major allele.</p>
</fn>
<fn id="t2-fn3">
<label>b</label>
<p><italic>P</italic> values were calculated by one-tailed Fisher’s exact
test.</p>
</fn>
<fn id="t2-fn4">
<p><italic>Note</italic>: Genomic position is based on NCBI builds GRCh38. Amino acid
position is based on NCBI reference sequence NP_001328.1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>